At the University of South Australia, researchers have found a way to wrap one of the world's most common chemotherapy drugs inside microscopic fatty capsules, guiding it more faithfully toward tumors and away from the healthy tissue it has long harmed as collateral. The advance — doubling the drug's effectiveness at reaching its target — does not end the suffering of cancer treatment, but it narrows the gap between cure and harm that has defined chemotherapy for generations. In a world where cancer touches one in six deaths, even a measured step toward precision carries the weight of hundreds
Australian researchers develop nano-delivery system to reduce chemotherapy side effects
Chemotherapy patients currently suffer severe side effects including nausea, vomiting, fatigue, hair loss, diarrhea, infections, and mouth sores that this advance could mitigate.
Patients could receive the same cancer-fighting benefit with substantially fewer side effects
Mark
So they've wrapped the drug in fat? That sounds almost too simple.
Mimi
It is simple in concept, but the execution matters enormously. The liposome acts like a protective envelope. It keeps the drug stable as it travels through the bloodstream and helps it accumulate in tumor tissue rather than spreading everywhere.
Luke
But liposomes aren't new. What exactly is new here?
Mimi
The measurement. They used micro-dialysis to prove, for the first time, that this approach actually reduces off-target damage. Before, researchers suspected it worked but couldn't measure it precisely enough.
Mark
And the numbers—100 percent more effective. That's a doubling of effectiveness?
Mimi
In targeting tumors, yes. The drug reaches cancer cells at twice the concentration compared to standard delivery.
Luke
But does that translate to fewer side effects in actual patients? The research shows it works in measurement, but has this been tested in people yet?
Mimi
The research is at the stage of demonstrating the principle. Clinical trials would come next.
Mark
So this is promising but not yet in hospitals.
Mimi
Correct. It's a crucial step forward, but the path from laboratory to patient care still requires testing.
Luke
And we should note—5-FU is one drug. Does this method work for other chemotherapy agents?
Mimi
That's the open question. The researchers focused on 5-FU because it's so widely used, but the principle could apply to other drugs.
Mark
How many patients in Australia would potentially benefit?
Mimi
With 150,000 new cancer diagnoses annually, and 5-FU being one of the most common treatments, the potential reach is substantial. But not every patient receives this drug.
The Pulse
- Chemotherapy's brutal side effects — nausea, hair loss, infections, and exhaustion — stem largely from drugs that cannot distinguish tumor from healthy tissue, a flaw that has persisted for decades.
- Australian scientists have now demonstrated that encasing the drug 5-FU inside liposomes, tiny fatty capsules, doubles its concentration at the tumor site while sparing surrounding cells from the worst of the damage.
- A key breakthrough was the use of micro-dialysis sampling, a technique precise enough to map exactly where the drug travels in the body — something conventional imaging has never been able to do.
- The findings mark a world-first in quantifying liposomal chemotherapy delivery, opening a credible path toward treatments that are both more effective and significantly less toxic.
- With 150,000 new cancer diagnoses in Australia each year, the research now moves toward the harder work of translating laboratory results into treatments patients can actually receive.
At the University of South Australia, researchers have found a way to wrap one of the world's most common chemotherapy drugs inside microscopic fatty capsules, guiding it more faithfully toward tumors and away from the healthy tissue it has long harmed as collateral. The advance — doubling the drug's effectiveness at reaching its target — does not end the suffering of cancer treatment, but it narrows the gap between cure and harm that has defined chemotherapy for generations. In a world where cancer touches one in six deaths, even a measured step toward precision carries the weight of hundreds of thousands of lives.
Researchers at the University of South Australia have developed a method to deliver chemotherapy far more precisely to cancer cells, wrapping the widely used drug 5-FU inside microscopic fatty capsules called liposomes. The result is a formulation that reaches tumors twice as effectively as conventional methods — while causing substantially less damage to the healthy tissue caught in the crossfire.
The problem is one medicine has long struggled to solve. 5-FU, among the most prescribed chemotherapy agents in the world, does not naturally concentrate in tumors. It disperses through the body indiscriminately, and patients pay the price: nausea, vomiting, hair loss, mouth sores, infections, and deep fatigue. With cancer claiming one in six deaths globally and roughly 150,000 new diagnoses in Australia each year, the cumulative weight of those side effects is immense.
The liposomal concept — encasing drugs in fatty membranes to protect them in transit and steer them toward tumors — has existed for years, but proving it works precisely enough to matter has been the obstacle. Lead researcher Clive Prestidge and his team cleared that obstacle using micro-dialysis, a minimally invasive technique that mapped exactly where the drug accumulated in the body. It is the first time this effect has been quantified with such clarity.
The implications, Prestidge suggests, could reshape treatment across multiple cancer types — from breast to colon cancer and beyond. The advance does not eliminate side effects, but it offers a meaningful path toward making a grueling treatment less overwhelming. The work now moves toward its next challenge: bringing what was proven in the laboratory into the hands of patients who need it.
A team of researchers at the University of South Australia has developed a method to deliver chemotherapy drugs more precisely to cancer cells while sparing healthy tissue from damage. The breakthrough centers on wrapping the widely used drug 5-FU, or Fluorouracil, inside microscopic fatty capsules called liposomes. When administered this way, the drug reaches tumors twice as effectively as conventional delivery methods, according to the scientists' findings.
The problem they set out to solve is straightforward but consequential. Chemotherapy saves lives, but it exacts a steep price. The 5-FU drug, one of the most commonly prescribed chemotherapy agents worldwide, does not naturally concentrate in tumor tissue. Instead, it disperses throughout the body, poisoning healthy cells alongside cancerous ones. Patients endure nausea, vomiting, hair loss, mouth sores, infections, fatigue, and digestive upheaval. Many become severely ill during treatment itself. With roughly 150,000 new cancer diagnoses in Australia each year, and cancer claiming one in six deaths globally, the cumulative toll of these side effects touches hundreds of thousands of people annually.
The liposomal approach is not entirely new—researchers have long understood that encasing drugs in fatty membranes could protect them during transit through the body and allow them to accumulate in tumors more effectively. But optimizing this method for chemotherapy has proven difficult. The challenge lies in measuring whether the strategy actually works. Traditional imaging techniques cannot track drug distribution with enough precision to confirm that liposomal formulations truly deliver more medicine to the tumor and less to surrounding tissue.
Clive Prestidge, lead researcher and co-director of the Centre for Pharmaceutical Innovation at UniSA, and his team solved this measurement problem using a technique called micro-dialysis. This minimally invasive sampling method allowed them to map exactly where the 5-FU drug accumulated in the body. The results showed that the liposomal formulation reduced tumor growth while cutting toxic damage to healthy cells. This is the first time researchers have quantified this effect with such precision.
Prestidge describes the implications as potentially transformative. Liposomal formulations work by keeping encapsulated drugs intact longer, allowing them to circulate until they reach their target. For chemotherapy, this means patients could receive the same cancer-fighting benefit with substantially fewer side effects—less nausea, less hair loss, fewer infections, less overall suffering during a treatment that is already grueling. The advance could reshape how multiple cancer types are treated, from breast cancer to colon cancer and beyond.
The research represents a world-first finding in how chemotherapy can be delivered. It does not eliminate side effects entirely, but it offers a path toward making a necessary treatment significantly less toxic. For the thousands of patients who undergo chemotherapy each year in Australia alone, the difference between current treatment and this optimized approach could mean the difference between managing illness and being overwhelmed by it. The work now moves toward the next phase: translating laboratory findings into treatments available to patients.
Notable Quotes
Chemotherapy is regularly administered to treat many different types of cancers, but one of the major setbacks of 5-FU is that it does not distribute well to tumor tissue and can cause high levels of off-target damage.— Professor Clive Prestidge, lead researcher at University of South Australia
Our micro-dialysis approach is the first to quantify how liposomal-specific delivery of 5-FU can reduce tumor growth with fewer toxic side effects. It has the potential to dramatically transform many cancer treatments.— Professor Clive Prestidge
Want the full story?
Read the original at The Canberra Times ↗
Health & Medicine